RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2007-01-01 Longarini, R; Buti, S; Bosio, G; Brighenti, M; Porzio, R; Negri, F; Passalacqua, R
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC
2019-01-01 Mazzaschi, G.; Minari, R.; Ferri, V.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Bordi, P.; Squadrilli, A.; Buti, S.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M.
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC)
2008-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC)
2008-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R
IMMUNE TUMOR MICROENVIRONMENT (I-TME) ANALYSES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) TREATED WITH SECOND LINE NIVOLUMAB: RESULTS FROM THE MEET-URO 18 STUDY
2022-01-01 Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Gandini, A.; Puglisi, S.; Borea, R.; Martelli, V.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G.
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial
2013-01-01 Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E
Impact of low doses of immunotherapy (LDI) with interleukin-2 (IL-2) and interferon alpha (IFNA) in metastatic renal cell cancer (MRCC) patients with different prognostic risk
2006-01-01 Buti, S; Buzio, C; Vaglio, A; Bongiovanni, C; Alberici, F; Brighenti, M; Dalla Chiesa, M; Tomasello, G; Passalacqua, R
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)
2017-01-01 De Giorgi, U; Procopio, G; Guida, A; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, Cn
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient's counselling preliminary analysis of the INVIDIa study
2017-01-01 Bersanelli, M; Castrignanò, P; Gambale, E; Cortellini, A; Tiseo, M; Natoli, C; Ficorella, C; Panni, S; Rossetti, S; Papa, A; Mazzoni, F; Facchini, G; De Giorgi, U; Procopio, G; Atzori, F; Sava, T; De Luca, E; Maestri, A; Massari, F; Buti, S
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab
2018-01-01 Mazzaschi, G; Facchinetti, F; Madeddu, D; Buti, S; Gelsomino, F; Ardizzoni, A; Aversa, F; Missale, G; Quaini, F; Tiseo, M
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC) | 1-gen-2007 | Longarini, R; Buti, S; Bosio, G; Brighenti, M; Porzio, R; Negri, F; Passalacqua, R | |
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC | 1-gen-2019 | Mazzaschi, G.; Minari, R.; Ferri, V.; Gnetti, L.; Bersanelli, M.; Cavazzoni, A.; Bordi, P.; Squadrilli, A.; Buti, S.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Petronini, P. G.; Missale, G.; Quaini, F.; Tiseo, M. | |
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC) | 1-gen-2008 | Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R | |
High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with oxaliplatin, folinic acid (FA), 5-fluorouracil (5-FU) and irinotecan (COFFI) in metastatic gastric cancer (MGC) | 1-gen-2008 | Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Brighenti, M; Lazzarelli, S; Auzzani, A; Curti, A; Martinotti, M; Passalacqua, R | |
IMMUNE TUMOR MICROENVIRONMENT (I-TME) ANALYSES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) TREATED WITH SECOND LINE NIVOLUMAB: RESULTS FROM THE MEET-URO 18 STUDY | 1-gen-2022 | Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Gandini, A.; Puglisi, S.; Borea, R.; Martelli, V.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G. | |
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial | 1-gen-2013 | Caffo, O; Sava, T; Basso, U; Buti, S; Lo Re, G; Sacco, C; Lodde, M; Facchini, G; Zustovich, F; Perin, A; Russo, L; Veccia, A; Galligioni, E | |
Impact of low doses of immunotherapy (LDI) with interleukin-2 (IL-2) and interferon alpha (IFNA) in metastatic renal cell cancer (MRCC) patients with different prognostic risk | 1-gen-2006 | Buti, S; Buzio, C; Vaglio, A; Bongiovanni, C; Alberici, F; Brighenti, M; Dalla Chiesa, M; Tomasello, G; Passalacqua, R | |
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP) | 1-gen-2017 | De Giorgi, U; Procopio, G; Guida, A; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, Cn | |
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient's counselling preliminary analysis of the INVIDIa study | 1-gen-2017 | Bersanelli, M; Castrignanò, P; Gambale, E; Cortellini, A; Tiseo, M; Natoli, C; Ficorella, C; Panni, S; Rossetti, S; Papa, A; Mazzoni, F; Facchini, G; De Giorgi, U; Procopio, G; Atzori, F; Sava, T; De Luca, E; Maestri, A; Massari, F; Buti, S | |
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab | 1-gen-2018 | Mazzaschi, G; Facchinetti, F; Madeddu, D; Buti, S; Gelsomino, F; Ardizzoni, A; Aversa, F; Missale, G; Quaini, F; Tiseo, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Articolo su rivista 113
- 1 Articolo su rivista::1.5 Abstra... 113
Data di pubblicazione
- 2020 - 2023 38
- 2010 - 2019 45
- 2004 - 2009 30
Editore
- ASCO pubs 11
- Elsevier 6
- SAGE PUBLICATIONS LTD 5
- ELSEVIER 4
- BioMed Central 2
- International Institute of Antica... 1
- LIPPINCOTT WILLIAMS & WILKINS 1
- SAGE 1
Rivista
- ANNALS OF ONCOLOGY 39
- JOURNAL OF CLINICAL ONCOLOGY 39
- TUMORI 8
- I SUPPLEMENTI DI TUMORI 5
- JOURNAL OF THORACIC ONCOLOGY 4
- JOURNAL OF CLINICAL ONCOLOGY 3
- ANTICANCER RESEARCH 2
- GIORNALE ITALIANO DI NEFROLOGIA 2
- JOURNAL FOR IMMUNOTHERAPY OF CANCER 2
- ANTICANCER RESEARCH 1
Keyword
- Poster presentation at AIOM 2022 1
Lingua
- eng 95
- ita 4
- fre 1
Accesso al fulltext
- no fulltext 110
- open 3